Market Cap
$4.3B
EWTX
Edgewise Therapeutics, Inc.
$41.27 ▲ +1.95%
Prev close $40.48Market cap$4.3B
ConsensusStrong Buy
12-mo target$52.62 (+27.5%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (5 insiders)High Impact Filing (7/10)27 New Institutional Positions11 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on EWTX right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (84%)
Inst. Holders
50 funds
Inst. Value
$2.6B
Inst. Activity
27 buys / 11 sells
Insider Activity
$0.00 buy / $9.8M sell
Insider Net $
-$9.8M
SEC Reports
9
Price chart 30d -1.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 short_volume
Aug 17, 2026 SEC Short Volume: EWTX — 64.5% short (0.6M / 0.9M)
Short: 587,783 | Exempt: 0 | TRF Vol: 911,814 | Short Ratio: 64.5% | Off-exchange volume (dark pool
Five C-suite insiders at Edgewise Therapeutics sold a total of ~$401K in open-market shares on August 12, 2026, followin
CLUSTER — Impact 4/10
CEO Kevin Koch and General Counsel John Moore sold a combined ~$468K in open-market sales on August 12, 2026, following
CLUSTER — Impact 3/10
Aug 13, 2026 Insider
Donovan Joanne M. sold 2,919 shares
CMO @ $43.41 ($126.7K)
Aug 12, 2026 Insider
KOCH KEVIN sold 8,276 shares
President and CEO @ $43.66 ($361.3K)
Aug 12, 2026 Insider
Aug 6, 2026 SEC MOORE JOHN R acquired via exercise 5,781 shares
General Counsel
Edgewise Therapeutics reported Q2 2026 net loss of $0.53/share, a 12.2% miss vs consensus of $-0.47, with no revenue. Th
8-K — Impact 7/10
Jun 30, 2026 Inst.
FMR LLC — DOUBLED
5,489,135 shares ($223.0M)
Analyst ratings buy % +1.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
84% rate it Buy or better · 19 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 21, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 20, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Aug 11, 2026 | Goldman Sachs | MAINTAIN | Neutral | 54% |
| Jul 20, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| Jul 9, 2026 | Oppenheimer | INITIATE | Outperform | 52% |
| Jul 6, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Jun 17, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Jun 17, 2026 | Goldman Sachs | MAINTAIN | Neutral | 54% |
| Jun 16, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jun 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 9 | 3 | 0 | 0 | 84% | |
| Aug 1, 2026 | 7 | 9 | 3 | 0 | 0 | 84% | |
| Jul 1, 2026 | 6 | 9 | 3 | 0 | 0 | 83% | |
| Jun 1, 2026 | 6 | 9 | 3 | 0 | 0 | 83% | |
| May 1, 2026 | 6 | 9 | 3 | 0 | 0 | 83% | |
| Apr 1, 2026 | 6 | 9 | 3 | 0 | 0 | 83% | |
| Mar 1, 2026 | 6 | 9 | 3 | 0 | 0 | 83% | |
| Feb 1, 2026 | 6 | 9 | 3 | 0 | 0 | 83% |
Price targets
Where 13 covering analysts think EWTX trades over the next 12 months.
$52.62 +27.5% upside Strong Buy
Current$41.27 Low$36.00 Median$53.00 High$66.00 13 analysts
$36.00$66.00
Analyst rating Buy· 1.5/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 2 bullish, 0 bearish, 1 mixed, 6 neutral · avg impact 4.7/10.
NEUTRALCLUSTER4/10
Five C-suite insiders at Edgewise Therapeutics sold a total of ~$401K in open-market shares on Augus
Aug 17, 2026
NEUTRALCLUSTER3/10
CEO Kevin Koch and General Counsel John Moore sold a combined ~$468K in open-market sales on August
Aug 15, 2026
MIXED8-K7/10
Edgewise Therapeutics reported Q2 2026 net loss of $0.53/share, a 12.2% miss vs consensus of $-0.47,
Aug 6, 2026
BULLISH8-K7/10
Edgewise Therapeutics completed the sale of its sevasemten muscular dystrophy program to Servier for
Jul 13, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 28, 2026
short_volume
Short Volume: EWTX — 64.5% short (0.6M / 0.9M)
Short: 587,783 | Exempt: 0 | TRF Vol: 911,814 | Short Ratio: 64.5% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: EWTX — 62.6% short (0.4M / 0.7M)
Short: 415,680 | Exempt: 0 | TRF Vol: 663,880 | Short Ratio: 62.6% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
Clinical Trial
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
Phase Phase 2 — COMPLETED
Sep 21, 2026
clinical_trial_readout
Results Pending: Sevasemten 10 mg (Phase 2) — Completed 14d ago
Trial: Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) Sponsor: Edgewise Therapeutics, Inc. Phase: Phase 2 | Completed: 2026-09-
Sep 21, 2026
short_volume
Short Volume: EWTX — 62.6% short (0.4M / 0.6M)
Short: 380,174 | Exempt: 300 | TRF Vol: 607,229 | Short Ratio: 62.6% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.81 | $-0.64–$11.45 | 819.9% | +0.0% | 1↑ 4↓ | $0.1B | 10 |
| Next Q | $-0.38 | $-0.78–$0.60 | 18.6% | +0.0% | 2↑ 5↓ | $0.0B | 12 |
| Current FY | $1.38 | $-2.42–$10.28 | 184.7% | +0.0% | 0↑ 5↓ | $0.1B | 10 |
| Next FY | $-1.82 | $-3.44–$-0.47 | -231.6% | +0.0% | 1↑ 6↓ | $0.0B | 11 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.807 | — |
| 7d ago | $2.807 | — |
| 30d ago | $2.807 | — |
| 60d ago | $1.133 | +1.675 |
| 90d ago | $1.133 | +1.675 |
Institutional ownership
Which big funds own EWTX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $2.6B total value (63,483,206 shares) as of 2026-Q2. Top holders: RA, BlackRock,, Jupiter. Net buying activity: 27 institutions added/increased vs 11 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 8,392,730 | $341.0M | 13.3% | — |
| BlackRock, Inc. | 6,606,336 | $268.4M | 10.5% | — |
| Jupiter Topco LLC | 6,075,331 | $246.9M | 9.6% | — |
| FMR LLC | 5,489,135 | $223.0M | 8.7% | DOUBLED +439.7% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4,728,623 | $192.1M | 7.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,860,670 | $156.9M | 6.1% | — |
| BAKER BROS. ADVISORS LP | 3,701,719 | $150.4M | 5.9% | TRIM -43.7% |
| GEODE CAPITAL MANAGEMENT, LLC | 2,174,051 | $88.3M | 3.5% | — |
| MORGAN STANLEY | 1,948,597 | $79.2M | 3.1% | — |
| STATE STREET CORP | 1,827,927 | $74.3M | 2.9% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | DOUBLED | 1,017,052 | 5,489,135 | +439.7% | $223.0M |
| BAKER BROS. ADVISORS LP | TRIM | 6,575,940 | 3,701,719 | -43.7% | $150.4M |
| Qube Research & Technologies Ltd | ADD | 825,910 | 1,252,507 | +51.7% | $50.9M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 557,260 | 786,456 | +41.1% | $32.0M |
| NORGES BANK | NEW | — | 510,140 | — | $20.7M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | — | 462,000 | — | $18.8M |
| RAYMOND JAMES FINANCIAL INC | DOUBLED | 19,678 | 317,565 | +1513.8% | $12.9M |
| PRUDENTIAL FINANCIAL INC | DOUBLED | 10,605 | 260,725 | +2358.5% | $10.6M |
| Schonfeld Strategic Advisors LLC | DOUBLED | 99,075 | 255,202 | +157.6% | $10.4M |
| JPMORGAN CHASE & CO | ADD | 147,573 | 203,151 | +37.7% | $8.5M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 50 transactions. Net -$9.8M — $0.00 bought, $9.8M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Donovan Joanne M. | CMO | SELL | 2,919 | $43.41 | $126.7K |
| Aug 12, 2026 | KOCH KEVIN | President and CEO | SELL | 8,276 | $43.66 | $361.3K |
| Aug 12, 2026 | MOORE JOHN R | General Counsel | EXERCISE | 5,781 | — | — |
| Aug 12, 2026 | KOCH KEVIN | President and CEO | SELL | 8,782 | $43.64 | $383.3K |
| Aug 12, 2026 | MOORE JOHN R | General Counsel | SELL | 99 | $44.50 | $4.4K |
| Aug 12, 2026 | MOORE JOHN R | General Counsel | SELL | 2,439 | $43.81 | $106.8K |
| Aug 12, 2026 | KOCH KEVIN | President and CEO | EXERCISE | 17,969 | — | — |
| Aug 12, 2026 | KOCH KEVIN | President and CEO | EXERCISE | 21,875 | — | — |
| Aug 12, 2026 | KOCH KEVIN | President and CEO | SELL | 913 | $44.33 | $40.5K |
| Aug 12, 2026 | MOORE JOHN R | General Counsel | SELL | 2,419 | $43.80 | $105.9K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for EWTX.
Shares short
9,543,843
Settlement Sep 15, 2026
Change vs prior
+2.1%
Semi-monthly cycle
Days to cover
8.0
At avg daily volume
Of shares outstanding
≈8.8%
Estimate — not % of float
All EWTX filing & press-release reports (9)
- CLUSTER reportAug 17, 2026
- CLUSTER reportAug 15, 2026
- 8-K reportAug 6, 2026
- 8-K reportJul 13, 2026
- 8-K reportJun 1, 2026
- 8-K reportMay 7, 2026
- DEFA14A reportApr 23, 2026
- 144 reportMar 27, 2026
- 8-K reportFeb 26, 2026